OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	198
Access in all areas? A round-up of developments in market access and health technology assessment: part 10	47
Journal of Comparative Effectiveness Research : 2022 year in review	46
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	38
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	32
Engaging veterans in the research process: a practical guide	29
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	29
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	29
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	24
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	24
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	22
Corrigendum	21
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	21
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	20
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	19
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	19
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	17
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	17
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	17
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	17
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	15
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	14
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	13
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	13
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	13

Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	13
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	12
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	12
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	12
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	12
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	12
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	11
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China	11
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	11
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	11
Access in all areas? A round-up of developments in market access and health technology assessment: part 11	11
Corrigendum	11
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	10
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	10
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	10
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	10
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	9
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	9
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	9
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	9
The triple win – implementation science benefits patients, healthcare systems and industry alike	9
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	9
Characterization of medical device randomized controlled trials with adaptive designs	8
How the use of standardized protocols may paradoxically worsen disparities for safety-net hospitals	8
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	8
COVID-19 clinical trials: who is likely to participate and why?	8
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	8
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	8
Impact analysis of expanding narrow-spectrum antibiotic use for children with ear, sinus and throat infections	8
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	8
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	8
Impact of lymph node dissection on overall survival and cancer-specific survival in elderly patients with early-stage non-small cell lung cancer: a SEER database analysis	8
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	8
Acceptability of external control-arm use in nononcology health technology assessment submissions	8
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	7
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	7
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	7
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	7
Corrigendum	7
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	7
Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US	7
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	7
Access in all areas? A round up of developments in market access and health technology assessment: part 1	7
Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	7
Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice	7
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	7
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	7
Impact of COVID-19 on chronic pain structures: data from French national survey	7

Navigating adalimumab biosimilars: an expert opinion	7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	7
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma	7
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	6
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
A value-based budget impact model for dronedarone compared with other rhythm control strategies	6
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison	6
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	6
Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease	6
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity	6
Expanding the learning health system model to be health literate	6
An economic evaluation of teledermatology care delivery for chronic skin diseases	6
COVID-19 complications in males and females: recent developments	5
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	5
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	5
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	5
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	5
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	5
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	5
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	5
How pharma can amplify product value with implementation science	5
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	5
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	5
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	5
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	5
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	5
Impact analysis of expanded access to ketamine for treatment-resistant depression	5
Clinical and economic burden among older adults with acromegaly in the United States	5
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	5
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	5
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	5
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma	5
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	5